PEN Stock Overview
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$140.38|
|52 Week High||US$293.20|
|52 Week Low||US$130.96|
|1 Month Change||-29.01%|
|3 Month Change||-39.38%|
|1 Year Change||-40.26%|
|3 Year Change||0.96%|
|5 Year Change||70.26%|
|Change since IPO||239.90%|
Recent News & Updates
|PEN||US Medical Equipment||US Market|
Return vs Industry: PEN underperformed the US Medical Equipment industry which returned -15.6% over the past year.
Return vs Market: PEN underperformed the US Market which returned -10.4% over the past year.
|PEN Average Weekly Movement||8.4%|
|Medical Equipment Industry Average Movement||10.3%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: PEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: PEN's weekly volatility (8%) has been stable over the past year.
About the Company
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names.
Penumbra Fundamentals Summary
|PEN fundamental statistics|
Is PEN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PEN income statement (TTM)|
|Cost of Revenue||US$290.82m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.17|
|Net Profit Margin||-0.83%|
How did PEN perform over the long term?See historical performance and comparison
Is Penumbra undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: PEN ($140.38) is trading above our estimate of fair value ($79.57)
Significantly Below Fair Value: PEN is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: PEN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: PEN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate PEN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: PEN is overvalued based on its PB Ratio (5.5x) compared to the US Medical Equipment industry average (2.5x).
How is Penumbra forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PEN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: PEN is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PEN's is expected to become profitable in the next 3 years.
Revenue vs Market: PEN's revenue (13.5% per year) is forecast to grow faster than the US market (8% per year).
High Growth Revenue: PEN's revenue (13.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PEN's Return on Equity is forecast to be low in 3 years time (6.7%).
How has Penumbra performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PEN is currently unprofitable.
Growing Profit Margin: PEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: PEN is unprofitable, and losses have increased over the past 5 years at a rate of 1.9% per year.
Accelerating Growth: Unable to compare PEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: PEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.4%).
Return on Equity
High ROE: PEN has a negative Return on Equity (-0.86%), as it is currently unprofitable.
How is Penumbra's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: PEN's short term assets ($690.3M) exceed its short term liabilities ($130.1M).
Long Term Liabilities: PEN's short term assets ($690.3M) exceed its long term liabilities ($212.2M).
Debt to Equity History and Analysis
Debt Level: PEN is debt free.
Reducing Debt: PEN has not had any debt for past 5 years.
Debt Coverage: PEN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: PEN has no debt, therefore coverage of interest payments is not a concern.
What is Penumbra current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PEN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PEN has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Adam Elsesser (59 yo)
Mr. Adam Elsesser serves as President at Penumbra, Inc. since May 2020. He Co-Founded Penumbra, Inc. in 2004 and has been its Chief Executive Officer since 2004. Mr. Elsesser has been the Chairman since Ja...
CEO Compensation Analysis
Compensation vs Market: Adam's total compensation ($USD497.79K) is below average for companies of similar size in the US market ($USD8.23M).
Compensation vs Earnings: Adam's compensation has increased whilst the company is unprofitable.
Experienced Management: PEN's management team is considered experienced (2.4 years average tenure).
Experienced Board: PEN's board of directors are considered experienced (6.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.3%.
Penumbra, Inc.'s employee growth, exchange listings and data sources
- Name: Penumbra, Inc.
- Ticker: PEN
- Exchange: NYSE
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$5.289b
- Shares outstanding: 37.68m
- Website: https://www.penumbrainc.com
Number of Employees
- Penumbra, Inc.
- One Penumbra Place
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/16 00:00|
|End of Day Share Price||2022/05/16 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.